Bibliography
- DeFrances CJ, Hall MJ. 2005 National Hospital Discharge Survey. Advance data from vital and health statistics; no 385. Hyattsville, MD, USA: National Center for Health Statistics; 2007. Available from: http://www.cdc.gov/ nchs/fastats/insurg.htm
- Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006;32(Suppl 1):98-110
- Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res 2001;58(6):710-9
- Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001;233(1):88-96
- Heffernan JK, Ponce RA, Zuckerman LA, et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol 2007;47(1):48-58
- Winterbottom NK, Kuo JM, Nguyen K, et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients. J Appl Res Clin Exp Ther 2002;2:1-12
- Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007;205(2):256-65
- Chapman WC, Lockstadt H, Singla N, et al. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost 2006;4(9):2083-5
- Lundblad RL, Bradshaw RA, Gabriel D, et al. A review of the therapeutic uses of thrombin. Thromb Haemost 2004;91(5):851-60
- Doria C, Fischer CP, Wood CG, et al. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 2008;24(3):785-94
- US Food and Drug Administration. FDA approves first clotting solution made using recombinant DNA technology. FDA News: US Food and Drug Administration. Available from: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01779.html [Last accessed 30 October 2008]
- FDA-RECOTHROM Product Approval Informaion. Available from: http://www.fda.gov/CbER/products/recothrom.htm
- Bishop PD, Lewis KB, Schultz J, Walker KM. Comparison of recombinant human thrombin and plasma-derived human α-thrombin. Semin Thromb Hemost 2006;32(Suppl 1):86-97
- Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103(6):879-87
- Badimon L, Meyer BJ, Badimon JJ. Thrombin in arterial thrombosis. Haemostasis 1994;24:69-80
- Greenberg CS, Archyuthan KE, Fenton JW. Factor XIIIa formation promoted by complexing of α-thrombin, fibrin, and plasma factor XIII. Blood 1987;69(3):867-71
- Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Pharmacology/Toxicology Review Memorandum; BLA 125248 Thrombin (Recombinant); 2007. Available from: http://www.fda.gov/ CBER/products/recothrom/recothrom091807mem.pdf
- Berrevoet F, De Hemptinne B. Clinical application of topical sealants in liver surgery: does it work? Acta Chir Belg 2007;107(5):504-7
- Pusateri AE, Holcomb JB, Bhattacharyya SN, et al. Different hypotensive responses to intravenous bovine and human thrombin preparations in swine. J Trauma 2001;50(1):83-90
- Gershon SK, Chang AC, Purvis WV, Salive M. Misadministration of topical bovine thrombin. JAMA 1999;282(20):1919
- Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998;62(20):1817-24
- Uchigasaki S, Takahashi H, Suzuki T. A case of delayed death after accidental intravenous injection of thrombin. Int J Legal Med 1998;111(4):202-4
- Erdogan D, Van Gulik TM. Evolution of fibrinogen-coated collagen patch for use as a topical hemostatic agent. J Biomed Mater Res B Appl Biomater 2008;85(1):272-8
- Weaver FA, Lew W, Granke K, et al. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg 2008;47(6):1266-73